Nomura Holdings’s PTC Therapeutics PTCT Stock Holding History

Nomura Holdings’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-20,000	Closed	-$537K	–	2034
2015 Q3	$537K	Buy	+20,000	New	+$855K	﹤0.01%	953

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Nomura Holdings's PTCT Position: Q2 2021 in Review

Nomura Holdings sold out of PTC Therapeutics (PTCT) in Q2 2021, closing a stake of 16,150 shares — an estimated $765K sold.

Nomura Holdings first reported a position in PTCT in Q3 2013 and held it in 12 quarters. The position peaked at $2M in Q1 2020. 183 funds tracked by Wall St. Rank hold PTCT as of Q2 2021.

Nomura Holdings reported no remaining PTC Therapeutics position as of Q2 2021 after selling out during the quarter.
Nomura Holdings sold 16,150 PTC Therapeutics shares in Q2 2021, an estimated $765K.
Nomura Holdings first reported a position in PTC Therapeutics in Q3 2013 and held it in 12 quarters.
Nomura Holdings's PTC Therapeutics position peaked at $2M in Q1 2020.
183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2021.

Based on Nomura Holdings's 13F filing for Q2 2021, filed 16 Aug 2021.